Table 1.

Clinical summary of Cohort 1 (n=230), 2 (n=115), and 3 (n=48). Cohorts 1 and 2 were sourced from BCC, and clinical characteristics are summarized for incident- (n=36, n=18), prevalent- (n=12, n=6), and no-cancer (n=182, n=91) participants. Cohort 3 was sourced from SPH/BCC and clinical characteristics are summarized for incident- (n=5), prevalent- (n=3), no-cancer (n=40) participants. Patients were randomly assisnged to Cohort 1 or 2 Values are displayed as mean values, unless otherwise specified

	Cohort 1			Cohort 2			Cohort 3
	Incident	Prevalent	No cancer	Incident	Prevalent	No cancer	Incident	Prevalent	No cancer
N	36	12	182	18	6	91	5	3	40
Age (mean)	64.4	62.1	62.1	64.6	65.5	61.8	64.6	64.3	62.6
Sex (% female)	44.4	50	46.2	50	83.3	45.1	40	66.6	47.5
Smoking status (mean %)
Current	50	25	45.6	55.6	33.3	47.3	20	33.3	47.5
Ex	50	75	54.4	44.4	66.7	52.7	60	0.0	52.5
Never	0	0	0	0	0	0	20	33.3	0
Pack-years smoked (mean)	51.1	48	47	55.3	47	44.8	50.7	37.8	48
Lung function (mean)
FEV1/FVC	67.3	62	71.3	66	65.2	72.1	73.6	79	67
FEV1	2.5	2.1	2.6	2.3	1.8	2.6	2.3	2.1	2.4
FEV1 % predicted	78.5	71.4	84.3	85.2	68.6	85.2	88	83.3	77.6
COPD status (mean %)
No COPD	36.1	33.3	57.1	38.9	33.3	63.7	80	100	45
Mild	19.4	8.3	18.1	16.7	0	17.6	0	0	5
Moderate	38.9	25	20.9	33.3	33.3	16.5	20	0	35
Severe	2.8	16.7	2.7	11.1	16.7	1.1	0	0	15
Very Severe	0	0	0	0	0	0	0	0	0
Follow-up time (mean, yr)
Total	9.7	9.5	10	10.1	8.4	10.1	7.6	7	9.8
To cancer	4.2	N/A	N/A	4.3	N/A	N/A	1.9	N/A	N/A
Cancer type
LUAD	42.4	88.9		38.9	66.7		100	100
LUSC	12.1	11.1		16.7	33.3		0	0
NSCLC	9.1	0		11.1	0		0	0
SCLC	12.1	0		5.6	0		0	0
Other	24.2	0		27.8	0		NA	NA